Our Blog
-
BioUtah Letter on Prioritizing Life Sciences Workers for Vaccine Distribution
December 3, 2020 Mr. Rich Lakin, MSPH, MPA Immunizations Director Utah Department of Health Bureau of Epidemiology PO…
-
ProLung Has a New Name, Gets $3.3 Million Private Placement and More…
ProLung, now IONIQ Sciences (IONIQ), has been on a roll! Last week, the company announced that they had fully…
-
SPARC Health Announces Second Cohort Applications, Building on Inaugural Program Success
SPARC Health, a collaborative effort between Park City Angels (PCA), BioUtah, BioHive, in partnership with Governor’s Office of…
-
SPARC Health, BioUtah Co-Host Shark Tank-Style Pitch Competition at 2026 Wilson Sonsini Entrepreneur & Investor Life Sciences Summit
Taking place on March 12, 2026, at the Hilton Salt Lake City Center, the competition provides early-stage healthcare…
-
JP Morgan Healthcare Conference Recap – Photo Gallery
Check out the photo gallery from the 2026 JP Morgan Healthcare conference in San Francisco.
-
Haemonetics to Acquire Vivasure Medical
The purchase is expected to expand Haemonetics’ impact in fast-growing markets for structural heart and endovascular procedures.
-
BD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026
-
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc…
-
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening…
-
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
-
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on…